Aclaris Therapeutics ACRS
NASDAQ ACRS
$4.28 +0.13 (+3.25%)
As of: Nov 11, 2026 · 11:49 AM EST

Aclaris Therapeutics (ACRS) Non-Current Deferred Revenue (2024 - 2026)

Updated

Analysis

Aclaris Therapeutics (ACRS) Non-Current Deferred Revenue (2024 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Aclaris Therapeutics 625.92 Mn 223.91 Mn 1.29 Mn
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 13.33 Mn
Jun 30, 2026 14.31 Mn
Mar 31, 2026 15.29 Mn
Dec 31, 2025 16.17 Mn
Sep 30, 2025 17.49 Mn
Jun 30, 2025 18.22 Mn
Mar 31, 2025 19.21 Mn
Dec 31, 2024 20.04 Mn
Sep 30, 2024 21.18 Mn
API Access

Aclaris Therapeutics Non-Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-current-deffered-revenue&ticker=ACRS&period=max&api_key=YOUR_API_KEY